Abstract: A composition including a standardized Wedelia chinensis extract and a method of treating an androgen-stimulated disorder with such a composition. Also provided are a method for qualifying a standardized preparation of a Wedelia chinensis extract for treating an androgen-stimulated disorder and a method for treating said disorder with a thus qualified preparation.

Abstract: The present invention relates to biomarkers, methods and assay kits for predicting prognosis and/or monitoring progression of prostate cancer. The biomarkers include a glycosyltransferases [core 1 beta-3-galactosyltransferase (C1GALT1) and/or ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3GAL1)] gene product, its saccharide substrate/product, and/or a galectin-4 gene product.

Abstract: A composition including a standardized Wedelia chinensis extract and a method of treating an androgen-stimulated disorder with such a composition. Also provided are a method for qualifying a standardized preparation of a Wedelia chinensis extract for treating an androgen-stimulated disorder and a method for treating said disorder with a thus qualified preparation.

Abstract: A method for preparing a standardized Wedelia chinensis extract and an extract prepared by the method. Also provided is a method for qualifying the standardized extract by characterizing its most abundant compounds and its biological activity in vitro. Additionally, a method is provided for treating an androgen-stimulated disorder with the qualified Wedelia chinensis extract.

Abstract: A vaccine composition is disclosed. The vaccine composition comprises: (a) a therapeutically effective amount of an influenza virus-like particle (VLP) comprising: (i) influenza M1, influenza M2, influenza hemagglutinin (HA), and influenza neuraminidase (NA) proteins; (b) Foot-and-mouth disease virus (FMDV) capsid protein VP3, recombinant FMDV VP3 (rVP3), VP3 peptide, or SUMO VP3; and (c) alum. Also disclosed is use of a vaccine composition according to the invention in the manufacture of a medicament for inducing an immunogenic response in a subject in need thereof.

Abstract: A vaccine composition is disclosed. The vaccine composition comprises: (a) a therapeutically effective amount of an influenza virus-like particle (VLP) comprising: (i) influenza M1, influenza M2, influenza hemagglutinin (HA), and influenza neuraminidase (NA) proteins; (b) Foot-and-mouth disease virus (FMDV) capsid protein VP3, recombinant FMDV VP3 (rVP3), VP3 peptide, or SUMO VP3; and (c) alum. Also disclosed is use of a vaccine composition according to the invention in the manufacture of a medicament for inducing an immunogenic response in a subject in need thereof.

Abstract: A method for preparing a standardized Wedelia chinensis extract and an extract prepared by the method. Also provided is a method for qualifying the standardized extract by characterizing its most abundant compounds and its biological activity in vitro. Additionally, a method is provided for treating an androgen-stimulated disorder with the qualified Wedelia chinensis extract.

Abstract: A pharmacological composition for use in inhibiting differentiation, functional activities, and population of granulo-cytic myeloid-derived suppressor cells (gMDSCs) and/or suppressing, tumor metastasis in a subject in need thereof is disclosed. The composition comprises a therapeutically effective amount of Bidens pilosa extract, or more than one polyacetylenic compounds purified or isolated from the B. pilosa extract, and a pharmaceutically acceptable carrier.

Abstract: An extract of Asplenium nidus L. includes pyropheophorbide a methyl ester (C34H36N4O3), pheophorbide a methyl ester (C35H36N4O5), 1-linleoyl-3-linolenoyl-glycerol (C39H66O5), 1-linleoyl-2,3-dipalmitoyl-rac-glycerol (C53H98O6) and 1,3-dipalmitoyl-sn-glycerol (C35H68O5). The extract of Asplenium nidus L. is obtained by using a method including steps of: solvent extraction, using an solvent to extract an Asplenium nidus L. sample and to obtain an extract, with a w/v ratio between the solvent and the Asplenium nidus L. sample being 50˜60 mg/ml; and column chromatography, fractionating the extract with water and ethanol as eluent to obtain several fractions including fraction a to fraction i, and further evaporating and lyophilizing fraction b, c, d or their combination to obtain an extract of Asplenium nidus L.

Abstract: Virus-like particles (VLPs) of mammalian-hosted viruses, such as SARS-CoV and influenza viruses, have been recombinantly produced from Vero cells. The VLPs closely emulate the exterior of authentic virus particles and are highly immunogenic. They can elicit not only humoral but also cellular immune responses in a mammal. Compositions and methods related to the VLPs are also described.

Abstract: Disclosed herein is a method for treating an androgen-stimulated disease in a subject in need thereof by administering to the subject a composition containing an effective amount of an inhibitor of I?B kinase subunit ? activity. The composition can also be administered to a subject at high risk for prostate cancer as a method for reducing the subject's risk thereof. A further method relates to identifying a modulator of transcriptional activity regulated by I?B kinase subunit ?. Still another method relates to determining the I?B kinase subunit ?-regulated transcriptional activity regulated by in a non-human mammalian test subject.

Abstract: Virus-like particles (VLPs) of mammalian-hosted viruses, such as SARS-CoV and influenza viruses, have been recombinantly produced from Vero cells. The VLPs closely emulate the exterior of authentic virus particles and are highly immunogenic. They can elicit not only humoral but also cellular immune responses in a mammal. Compositions and methods related to the VLPs are also described.

Abstract: An extract of Asplenium nidus L. includes pyropheophorbide a methyl ester (C34H36N4O3), pheophorbide a methyl ester (C35H36N4O5), 1-linleoyl-3-linolenoyl-glycerol (C39H66O5), 1-linleoyl-2,3-dipalmitoyl-rac-glycerol (C53H98O6) and 1,3-dipalmitoyl-sn-glycerol (C35H68O5). The extract of Asplenium nidus L. is obtained by using a method including steps of: solvent extraction, using an solvent to extract an Asplenium nidus L. sample and to obtain an extract, with a w/v ratio between the solvent and the Asplenium nidus L. sample being 50˜60 mg/ml; and column chromatography, fractionating the extract with water and ethanol as eluent to obtain several fractions including fraction a to fraction i, and further evaporating and lyophilizing fraction b, c, d or their combination to obtain an extract of Asplenium nidus L.

Abstract: An extract of Asplenium nidus L. includes pyropheophorbide a methyl ester (C34H36N4O3), pheophorbide a methyl ester (C35H36N4O5), 1-linleoyl-3-linolenoyl-glycerol (C39H66O5), 1-linleoyl-2,3-dipalmitoyl-rac-glycerol (C53H98O6) and 1,3-dipalmitoyl-sn-glycerol (C35H68O5). The extract of Asplenium nidus L. is obtained by using a method including steps of: solvent extraction, using an solvent to extract an Asplenium nidus L. sample and to obtain an extract, with a w/v ratio between the solvent and the Asplenium nidus L. sample being 50˜60 mg/ml; and column chromatography, fractionating the extract with water and ethanol as eluent to obtain several fractions including fraction a to fraction i, and further evaporating and lyophilizing fraction b, c, d or their combination to obtain an extract of Asplenium nidus L.

Abstract: Virus-like particles (VLPs) of mammalian-hosted viruses, such as SARS-CoV and influenza viruses, have been recombinantly produced from Vero cells. The VLPs closely emulate the exterior of authentic virus particles and are highly immunogenic. They can elicit not only humoral but also cellular immune responses in a mammal. Compositions and methods related to the VLPs are also described.

Abstract: Disclosed herein is a method for treating an androgen-stimulated disease in a subject in need thereof by administering to the subject a composition containing an effective amount of an inhibitor of I?B kinase subunit ? activity. The composition can also be administered to a subject at high risk for prostate cancer as a method for reducing the subject's risk thereof. A further method relates to identifying a modulator of transcriptional activity regulated by I?B kinase subunit ?. Still another method relates to determining the I?B kinase subunit ?-regulated transcriptional activity regulated by in a non-human mammalian test subject.

Abstract: An extract of Asplenium nidus L. includes pyropheophorbide a methyl ester (C34H36N4O3), pheophorbide a methyl ester (C35H36N4O5), 1-linleoyl-3-linolenoyl-glycerol (C39H66O5), 1-linleoyl-2,3-dipalmitoyl-rac-glycerol (C53H98O6) and 1,3-dipalmitoyl-sn-glycerol (C35H68O5). The extract of Asplenium nidus L. is obtained by using a method including steps of: solvent extraction, using an solvent to extract an Asplenium nidus L. sample and to obtain an extract, with a w/v ratio between the solvent and the Asplenium nidus L. sample being 50-60 mg/ml; and column chromatography, fractionating the extract with water and ethanol as eluent to obtain several fractions including fraction a to fraction i, and further evaporating and lyophilizing fraction b, c, d or their combination to obtain an extract of Asplenium nidus L.

Abstract: Disclosed herein is a method for treating an androgen-stimulated disease in a subject in need thereof by administering to the subject a composition containing an effective amount of an inhibitor of I?B kinase subunit ? activity. The composition can also be administered to a subject at high risk for prostate cancer as a method for reducing the subject's risk thereof. A further method relates to identifying a modulator of transcriptional activity regulated by I?B kinase subunit ?. Still another method relates to determining the I?B kinase subunit ?-regulated transcriptional activity regulated by in a non-human mammalian test subject.

Abstract: The present invention discloses certain diterpenes that can be used to inhibit androgen receptor activity, induce apoptosis and block cell cycle progression of androgen receptor-dependent cells. Androgen receptor has been associated with various diseases such as prostate cancer, androgeneic alopecia, breast cancer, acne etc. Accordingly, the present invention further discloses methods of treating androgen receptor-associated diseases by administering the disclosed diterpenes.

Abstract: Virus-like particles (VLPs) of mammalian-hosted viruses, such as SARS-CoV and influenza viruses, have been recombinantly produced from Vero cells. The VLPs closely emulate the exterior of authentic virus particles and are highly immunogenic. They can elicit not only humoral but also cellular immune responses in a mammal. Compositions and methods related to the VLPs are also described.